- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CHIESI FARMACEUTICI Aktie jetzt für 0€ handeln | |||||
| Do | Chiesi Group: Chiesi Advances Its Carbon Minimal Inhaler Journey as European Submissions for Its Single Inhaler Triple Therapy (SITT) and ICS/LABA Combination Next-Generation Propellant pMDIs Are Validated | 328 | Business Wire | Key Highlights
Regulatory submissions for next-generation propellant pMDIs (pressurized metered-dose inhalers) across Chiesi's Single Inhaler Triple Therapy (SITT; or ICS/LABA/LAMA) and fixed... ► Artikel lesen | |
| 28.08. | Chiesi Global Rare Diseases Demonstrates Its Ongoing Commitment to the Rare Disease Community at the Society of Inborn Errors of Metabolism (SSIEM) 2026 Annual Symposium | 455 | GlobeNewswire (Europe) | -- Chiesi's abstract presentations highlight clinical insights and patient-reported outcomes in
Fabry disease and alpha-mannosidosis --
-- Rooted in patient voice and scientific rigor, this... ► Artikel lesen | |
| 27.07. | After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration | 26 | FierceBiotech | ||
| 25.06. | Chiesi Group and Arbor Biotechnologies Announce ABO-101 Granted Orphan Drug Designation by European Commission for Primary Hyperoxaluria | 698 | GlobeNewswire (Europe) | ABO-101 is an investigational gene editing therapy designed to address the underlying disease biology of PH1 by reducing hepatic oxalate production
Orphan Drug Designation (ODD) highlights the... ► Artikel lesen | |
| 12.06. | Chiesi Group Completes $1.64 Billion Acquisition Of KalVista Pharmaceuticals | 4 | pulse2.com | ||
| 11.06. | Chiesi Group Acquires KalVista Pharmaceuticals for $1.9B | 1 | Contract Pharma | ||
| 11.06. | Chiesi completes acquisition of KalVista for $27 per share | 2 | Investing.com | ||
| 11.06. | Chiesi schließt Übernahme von KalVista für 27 $ pro Aktie ab | 5 | Investing.com Deutsch | ||
| 11.06. | KalVista Pharmaceuticals, Inc.: Chiesi Group Completes Acquisition of KalVista Pharmaceuticals | 721 | Business Wire | Positioned to Expand Patient Access and Accelerate Impact in Rare Diseases
Chiesi Group ("Chiesi"), an international research-focused biopharmaceutical group and certified B Corp, today announced... ► Artikel lesen | |
| 05.06. | Chiesi Global Rare Diseases Announces European Commission Approval of LOJUXTA (lomitapide) - Capsules for Paediatric Use in Homozygous Familial Hypercholesterolaemia (HoFH) | 423 | GlobeNewswire (Europe) | European Commission approval expands the indication of lomitapide in the European Union (EU) to include children 5 years of age and older with HoFH, an ultra-rare genetic disorder affecting LDL-cholesterol... ► Artikel lesen | |
| 03.06. | Chiesi Global Rare Diseases to Launch the Second Edition of Find For Rare at 2026 ERA Congress to Advance Research in Lysosomal Storage Disorders | 502 | GlobeNewswire (Europe) | -- At ERA 2026, Chiesi will contribute to advancing the scientific understanding of Fabry disease and nephropathic cystinosis through real-world experience and clinical outcomes, supporting the needs... ► Artikel lesen | |
| 20.05. | Chiesi Group appoints Maria Paola Chiesi as New Chair | 1 | PMLiVE | ||
| 20.05. | Chiesi Group Announces New Chair and Vice Chair | 510 | Business Wire | Highlights: Planned transition in the Chair and Vice Chair roles reflects the Chiesi family's long-term commitment to continuity, shared value and responsible governance across generations... ► Artikel lesen | |
| 12.05. | Laufende Fusionskontrollverfahren: Chiesi Farmaceutici S.p.A., Parma/IT (Valline S.r.l., Parma/IT); Erwerb sämtlicher Anteile an und alleiniger Kontrolle über KalVista Pharmaceuticals, Inc., Framingham/MA/USA | 563 | Bundeskartellamt | Datum der Anmeldung:08.05.2026Aktenzeichen:B3-63/26Unternehmen:Chiesi Farmaceutici S.p.A., Parma/IT (Valline S.r.l., Parma/IT); Erwerb sämtlicher Anteile an und alleiniger Kontrolle über KalVista Pharmaceuticals... ► Artikel lesen | |
| 05.05. | Chiesi übernimmt KalVista und erweitert damit globales Portfolio für seltene Krankheiten | 13 | Bionity.com | ||
| 30.04. | Chiesi widens rare disease portfolio with $1.9bn KalVista buyout | 4 | Pharmaceutical Technology | ||
| 30.04. | Jones Trading downgrades Kalvista stock to hold on Chiesi acquisition | 4 | Investing.com | ||
| 29.04. | Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition | 6 | MedCity News | ||
| 29.04. | Italienische Pharmafirma Chiesi schluckt US-Rivalen KalVista | 10 | Reuters Deutschland | ||
| 29.04. | Chiesi signs $1.9bn deal to buy KalVista and its HAE drug | 10 | pharmaphorum |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 48,850 | -0,99 % | MARKET TALK/US-Gericht weist Antrag auf Verlegung von Bayer-Glyphosat-Vergleich ab | DJ MARKET TALK/US-Gericht weist Antrag auf Verlegung von Bayer-Glyphosat-Vergleich ab
Kläger gegen den Bayer-Konzern in den USA sind in der Berufungsinstanz mit dem Versuch gescheitert, die Zuständigkeit... ► Artikel lesen | |
| MERCK KGAA | 135,70 | -1,56 % | Aktien Frankfurt Ausblick: Dax knapp im Minus - Rutsch unter 21-Tage-Linie | FRANKFURT (dpa-AFX) - Für den Dax zeichnen sich nach dem schwachen Wochenauftakt am Dienstag weitere moderate Verluste ab. Eine Stunde vor Handelsbeginn signalisierte der X-Dax als außerbörslicher... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 5,350 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Successfully completed human factors validation study and pharmacokinetic study for Anaphylm (dibutepinephrine) sublingual filmRemains on track to resubmit Anaphylm NDA to the FDA in Q3 2026Continues... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 16,340 | 0,00 % | Generate Biomedicines stock price target raised to $30 by H.C. Wainwright on asthma data | ||
| ETON PHARMACEUTICALS | 59,98 | 0,00 % | PAUL MAIER V At Eton Pharmaceuticals Executes Options Exercise, Realizing $2.84M | ||
| OMNIAB | 4,740 | -0,21 % | Veraxa Biotech AG: VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb | VXA-222 advances into next phase at VERAXAZURICH, SWITZERLAND, July 27, 2026 --
VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies... ► Artikel lesen | |
| LB PHARMACEUTICALS | 47,490 | 0,00 % | LB Pharmaceuticals Inc: LB Pharmaceuticals to Participate in Upcoming September Investor Events | ||
| NOVO NORDISK | 40,155 | -1,69 % | Novo Nordisk: Charttechnik! Aktie vor der Trendwende nach oben! | © Foto: Pavel Danilyuk auf Pexels (Symbolbild)Ein verlorenes Studienduell gegen Eli Lilly und eine Aktie, die schon seit Monaten unter Druck steht. Dennoch kommt gerade jetzt ein Chartsignal, das Hoffnungen... ► Artikel lesen | |
| ELI LILLY | 997,80 | +0,06 % | Milliarden für Zelltherapien, neue Regeln der FDA: Warum Eli Lilly, Johnson & Johnson und Mesoblast jetzt im Fokus stehen | ||
| GELTEQ | 0,889 | -0,53 % | Gelteq Limited: Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs | MELBOURNE, Australia, June 17, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) ("Gelteq" or the "Company"), a biotechnology company developing a proprietary gel-based delivery platform for... ► Artikel lesen | |
| KARDIGAN | 20,680 | 0,00 % | Citi's U.S. Consumer Cards Business To Buy Kard Financial For Undisclosed Terms | WASHINGTON (dpa-AFX) - Banking major Citigroup Inc. (C) announced late Thursday that its U.S. Consumer Cards business has agreed to acquire Kard Financial, a commerce media and rewards platform.... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 12,185 | 0,00 % | Kazia Therapeutics Limited: Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy | Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further... ► Artikel lesen | |
| APNIMED | 27,980 | +0,61 % | Apnimed, Inc.: Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 68,09 | +0,10 % | Levoit and Cosori: 5 Back to School Wellness Heroes for the Bright Minds of Tomorrow | DUBAI, UAE, Aug. 21, 2026 /PRNewswire/ -- Levoit and Cosori unveil five smart home solutions to tackle back to school stresses: polluted indoor air, relentless AC dryness, post snack floor... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 1,205 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States | Everest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated 3-6 Million Chinese Patients with PSVT Approval Triggers $2.0 Million Payment to Milestone Pharmaceuticals... ► Artikel lesen |
Das Unternehmen CHIESI FARMACEUTICI SPA kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHIESI FARMACEUTICI SPA finden Sie auf Wallstreet Online.